STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today
released the initial technical protocols for AVA Antibody Testing
and will make these available to all existing Attana
In close collaboration with Linnaeus University Attana
application specialists have been performing studies on serum
samples to detect and characterize COVID-19 antibodies using
the Attana Cell™ 200 system. By optimizing the testing procedures,
two protocols have now successfully been established and
preparations are being made for the scientific publication of
corresponding technical notes.
The AVA Antibody-Testing protocols are comprised of two distinct
components: (1) AVA AB Validation and (2) AVA AB Assurance.
AVA AB Validation provides laboratories the ability
to validate existing antibody test results. Since existing tests
have not yet been proven reliable, the goal of this protocol is to
confirm positive and/or negative antibody test results and thus
improve the reliability of results.
AVA AB Assurance enables laboratories to both quantify
and quality test antibody presence in each serum sample by
determining the active concentration of antibodies.
The benefit of the AVA Antibody-testing platform is that it not
only ensures that correct antibody test results are given, but also
provides insights into potential immunity and sustained immunity.
By collecting data on the quantity and quality of antibodies in a
serum sample and comparing these to samples taken at a later date,
a full immunity profile could be established and maintained over
time. Additionally, if/when a COVID-19 vaccine becomes available,
the AVA platform can be used to determine who needs to be
vaccinated and how well they respond to the vaccination.
The release of these initial protocols enables any Attana Cell
200 instrument to be employed in COVID-19 antibody testing with
minor modifications and the addition of the necessary Attana
consumables and reagents. The newly launched Attana Cell™ 250
system will be delivered as an optimized system for the AVA
Attana continuously works to improve system performance and will
update customers with optimized protocols as they become
For more information, please contact:
CEO Attana AB
The Board of directors for Attana consider that the information
in this press release is not likely to have a significant effect on
the share price, but is of general interest for the shareholders
and hence should be communicated.
This information was brought to you by Cision
The following files are available for download:
Release of initial
Attana Virus Analytics-AVA testing protocols